Étiquette : animal model

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models, Claire J. Foldi et al., 2020

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models Claire J. Foldi, Paul Liknaitzky, Martin Williams, Brian J. Oldfield Frontiers in Neuroscience, 2020 | Volume 14 | Article 43 : 1-8 doi : 10.3389/fnins.2020.00043   Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN [...]

Lire la suite

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J. et al., 2014

Therapeutic potential of cannabinoids in schizophrenia, KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. Recent Patents on CNS Drug Discovery, 2014, 9, (1), 13-25. Doi : 10.2174/1574889809666140307115532   Abstract Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydro-cannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoyl-glycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during [...]

Lire la suite